SGLT2 抑制剂:为科医生提供广泛影响的治疗选择
Antonio Granata1, Francesco Pesce2, Massimo Iacoviello3
1Nephrology and Dialysis Unit, "Cannizzaro" Emergency Hospital, Catania, Italy.
Frontiers in nephrology
|September 7, 2023
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 除了糖尿病管理之外,还提供了显著的心血管和保护. 这些药物在各种疾病中显示出广泛的益处,改善了患者的治疗结果并改变了临床实践.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖共运输体2抑制剂 (SGLT2i) 最初是作为抗糖尿病药物开发的.
- 新出现的证据突出显示,它们的益处超越了血糖控制,扩展到心血管和脏健康.
研究的目的:
- 审查与SGLT2抑制剂相关的多方面的机制和临床结果.
- 为了强调它们对心血管和脏保护的影响,无论糖尿病状况如何.
主要方法:
- 文献综述和对SGLT2抑制剂临床试验数据的分析.
- 检查潜在的心脏和脏保护的病理生理机制.
- 亚组分析,包括患有IgA脏病的患者.
主要成果:
- SGLT2i激活管体球反,减少脏缺氧和氧化应激,抑制肝素,并限制 podocyte 损伤.
- 心脏保护作用包括改善心脏新陈代谢,减少纤维化和减少阿迪波金生产.
- 在血压控制,BMI降低,白蛋白尿,中风,心脏病和心血管死亡率方面表现出有效性.
结论:
- SGLT2 抑制剂对脏和心血管有显著的益处,即使在非糖尿病患者中也是如此.
- 它们的广泛的病理生理影响和有利的安全概况正在改变临床干预以获得重大健康结果.
相关概念视频
Oral Hypoglycemic Agents: Glinides
183
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
183
Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Glucagon-like Receptor Agonists
357
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
357
Secondary Active Transport
7.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460


